AMENDED CLAIMS

1) A process for the preparation of a composite containing a drug dispersed in an organic carrier, wherein the drug is massively dispersed (in bulk) within the particles of said organic carrier and it is present in amorphous form in a quantity greater than or equal to 50%, comprising the following steps:
a) forming a mixture of a drug with an organic carrier selected from the group consisting of water-soluble complexing agents chosen from cyclodextrins and maltodextrins, water-insoluble cross-linked polymers and mixtures thereof;
b) irradiating the mixture obtained in a), with microwaves, wherein the microwave power is modulated so that the temperature of the mixture increases until it reaches a value higher than the melting temperature of the drug and it is then maintained constant at said value for at least 5 minutes.

2) Process according to claim 1, wherein in step a) a wet mixture is formed by adding a solvent.

3) Process according to claim 2, wherein said solvent is water.

4) The process according to claim 3, in which said wet mixture is formed by adding water to the carrier-drug composite in a quantity comprised of between 0.1 ml/g and 5 ml/g with respect to the dry mixture of the composite.

5) The process according to claims 2 to 4, in which the pressure at which the irradiation is carried out is comprised of between 1 and 20 bar.

6) A process according to claims 1 to 4, wherein step b) is carried out in a container constituted of a dielectric material having coupling capacity with the microwaves.

7) The process according to claim 6, wherein said dielectric material is polytetrafluoroethylene loaded with graphite.

8) The process according to the claims 1 to 7, in which the irradiation with microwaves is carried out in an power range comprised of between 100 W and 5000 W, for an overall time up to 120 minutes.

9) A process according to claims 1 to 8 wherein said cross-linked polymer is selected form the group consisting of cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethylcellulose, cross-linked starch, cross-linked dextran, cross-linked polystyrene and cross-linked β-cyclodextrin.

10)A process according to claims 1 to 9 wherein said drug is a drug sparingly soluble in water.

11)A composite containing a drug dispersed in carrier consisting of a water soluble complexing agent selected from cyclodextrins and maltodextrins, wherein the drug is massively dispersed (in-bulk) within the particles of said complexing agent and it is present in amorphous form in a quantity greater than or equal to 50 % by weight, with respect to the total of drug present in the composite.

12)A composite according to claim 10, wherein said cyclodextrins are selected from alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin and derivatives thereof.

13)A composite according to claims 11 or 12, wherein the drug and the carrier are present in weight ratios comprised of between 1:0.5 and 1:20.

14)A composite according to claim 13, wherein the drug and the carrier are present in weight ratios comprised of between 1:1 and 1:10.

15)A composite according to claims 11 to 14, wherein said carrier has a surface area comprised of between 0.05 m^2/g and 20 m^2/g.

16)A composite according to claims 11 to 15, wherein said drug is a drug sparingly

soluble in water.

17)A composite according to claim 16, wherein said drug is selected from nimesulide, ibuprofen, nifedipine, grisofulvine, piroxicam, progesterone, lorazepam.

18)A composite as claimed in claims 11 to 17, for use in therapy.

19)A pharmaceutical composition containing a composite as claimed in claims 11 to 18, optionally associated with pharmaceutically acceptable excipients.

20)A pharmaceutical composition according to claim 19, formulated as a granulate, pill, mini-pill, capsule, micro-capsule.